ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Evaluation of patients diagnosed with primary Sjogren's syndrome with and without pulmonary involvement.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical, serological, and hematological profiles according to age at diagnosis in primary Sjögren disease: a single-center cross-sectional study.Rheumatology international · 2026Article
- Impaired pulmonary function associated with subclinical myocardial injury in primary Sjögren's syndrome: a preliminary cardiac magnetic resonance study.Clinical rheumatology · 2026Article
- Late-Onset Sjögren disease: A different clinical entity?Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimInterstitial lung disease (ILD) is the most severe pulmonary complicationin Primary Sjögren's Syndrome (pSS). We aimed to evaluate and compare the pulmonary involvement patterns, respiratory parameters, clinical, radiological, pathological, and laboratory features, disease activity scores, treatment choices, and the relationships between these findings at diagnosis in pSS patients with and without pulmonary involvement.
methodsPatients at Ankara Ataturk Sanatorium Training and Research Hospital were included in the analysis. Patients with ILD who met the classification criteria were included as the study group. Patients who met the SS classification criteria but had no findings in the lungs were included as the control group.
resultsThe median disease duration of ILD patients included in the study was 9.98 months. In pSS patients, patients with ILD had demographic (older age, male gender, more frequent smoking), symptomatology (frequent dry eyes), auto-antibody positivity (more frequent antinuclear antibodies (ANA), anti-Sjögren's Syndrome-related antigen A (SS-A), anti-Sjögren's Syndrome-related antigen B (SS-B)), higher disease activity and more frequent immunosuppressive use. When patients with pSS and ILD were compared according to high resolution computed tomography (HRCT) uptake pattern as nonspecific interstitial pneumonia (NSIP) (fibrotic or not) and unclassified, there were more male gender, lower forced vital capacity (FVC) values, and more frequent immunosuppressive and anti-fibrotic use in the NSIP group. When patients with ILD were classified according to gender, males had more smoking, SSB positivity, fibrotic NSIP, and lower FVC and diffusing lung capacity for carbon monoxide (DLCO) values.
conclusionA multidisciplinary approach involving pulmonologists, radiologists, and rheumatologists who are experts in ILD is important to increase diagnostic reliability. Pulmonary involvement in pSS is an important cause of morbidity and mortality and should be managed more carefully in male patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.